<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Longeveron Llc — News on 6ix</title>
    <link>https://6ix.com/company/longeveron-llc</link>
    <description>Latest news and press releases for Longeveron Llc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/longeveron-llc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835915c78dffbe2df1026b4.webp</url>
      <title>Longeveron Llc</title>
      <link>https://6ix.com/company/longeveron-llc</link>
    </image>
    <item>
      <title>Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-granted-chinese-patent-for-potency-assay-methods-for-assessing-human-mesenchymal-stem-cells-mscs</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-granted-chinese-patent-for-potency-assay-methods-for-assessing-human-mesenchymal-stem-cells-mscs</guid>
      <pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
      <description>The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a</description>
    </item>
    <item>
      <title>Longeveron Announces 2025 Full Year Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-announces-2025-full-year-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-announces-2025-full-year-financial-results-and-provides-business-update</guid>
      <pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
      <description>On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential</description>
    </item>
    <item>
      <title>Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-to-report-2025-full-year-financial-results-and-host-conference-call-on-march-17-2026-8</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-to-report-2025-full-year-financial-results-and-host-conference-call-on-march-17-2026-8</guid>
      <pubDate>Thu, 12 Mar 2026 13:00:00 GMT</pubDate>
      <description>MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:</description>
    </item>
    <item>
      <title>Longeveron Announces Closing of Private Placement of up to $30 Million</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-announces-closing-of-private-placement-of-up-to-dollar30-million-8</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-announces-closing-of-private-placement-of-up-to-dollar30-million-8</guid>
      <pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
      <description>$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left</description>
    </item>
    <item>
      <title>Longeveron Announces Private Placement of up to $30 Million</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-announces-private-placement-of-up-to-dollar30-million-16</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-announces-private-placement-of-up-to-dollar30-million-16</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left</description>
    </item>
    <item>
      <title>Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveronr-results-of-phase-2b-clinical-trial-demonstrating-stem-cell-therapy-improved-condition-of-patients-with-age-related-frailty-published-in-cell-stem-cell</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveronr-results-of-phase-2b-clinical-trial-demonstrating-stem-cell-therapy-improved-condition-of-patients-with-age-related-frailty-published-in-cell-stem-cell</guid>
      <pubDate>Wed, 25 Feb 2026 16:05:00 GMT</pubDate>
      <description>Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in Cell Stem Cell, a Cell Press Journal. The Phase 2b results demonstrated that intrav</description>
    </item>
    <item>
      <title>Longeveron® Appoints Stephen H. Willard as Chief Executive Officer</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-appoints-stephen-h-willard-213000640</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-appoints-stephen-h-willard-213000640</guid>
      <pubDate>Fri, 13 Feb 2026 21:30:00 GMT</pubDate>
      <description>Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the t</description>
    </item>
    <item>
      <title>Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-applauds-passage-mikaela-naylon-141500896</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-applauds-passage-mikaela-naylon-141500896</guid>
      <pubDate>Thu, 05 Feb 2026 14:15:00 GMT</pubDate>
      <description>Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron’s laromestrocel Hypoplastic Left Heart Syndrome (</description>
    </item>
    <item>
      <title>Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-granted-japan-patent-potency-141500765</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-granted-japan-patent-potency-141500765</guid>
      <pubDate>Thu, 29 Jan 2026 14:15:00 GMT</pubDate>
      <description>Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeveron’s growing international patent p</description>
    </item>
    <item>
      <title>Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-announces-fda-grants-type-141500527</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-announces-fda-grants-type-141500527</guid>
      <pubDate>Mon, 26 Jan 2026 14:15:00 GMT</pubDate>
      <description>ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationLaromestrocel HLHS program has the potential to address an unmet medical need with significant U.S. market opportunitiesEven with current standa</description>
    </item>
    <item>
      <title>Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-selected-startup-health-alzheimer-141500064</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-selected-startup-health-alzheimer-141500064</guid>
      <pubDate>Mon, 29 Dec 2025 14:15:00 GMT</pubDate>
      <description>Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditionsSupported by Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates VenturesApollo House, the Founders &amp; Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwideLongeveron will also be hosting meetings with institutional investors and potential partners during the</description>
    </item>
    <item>
      <title>Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-granted-u-patent-method-141500775</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-granted-u-patent-method-141500775</guid>
      <pubDate>Wed, 17 Dec 2025 14:15:00 GMT</pubDate>
      <description>The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of lifeFemale sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy womenLongeveron anticipates entering into licensing or partnering agreements for the potential development and commercialization of stem cell</description>
    </item>
    <item>
      <title>Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-chief-science-officer-chief-141500004</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-chief-science-officer-chief-141500004</guid>
      <pubDate>Wed, 03 Dec 2025 14:15:00 GMT</pubDate>
      <description>Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Offic</description>
    </item>
    <item>
      <title>Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-granted-canadian-patent-method-141500177</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-granted-canadian-patent-method-141500177</guid>
      <pubDate>Tue, 02 Dec 2025 14:15:00 GMT</pubDate>
      <description>The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathyNon-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantationNo approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan,</description>
    </item>
    <item>
      <title>Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-mri-biomarker-data-linking-170000280</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-mri-biomarker-data-linking-170000280</guid>
      <pubDate>Mon, 01 Dec 2025 17:00:00 GMT</pubDate>
      <description>Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple key brain regions, including key Alzheimer’s disease-associated regions, most notably in the hippocampusReduction in hippocampal neuroinflammation, meas</description>
    </item>
    <item>
      <title>Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-laromestrocel-data-alzheimer-disease-141500239</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-laromestrocel-data-alzheimer-disease-141500239</guid>
      <pubDate>Wed, 19 Nov 2025 14:15:00 GMT</pubDate>
      <description>Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” has been selected fo</description>
    </item>
    <item>
      <title>Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-granted-u-patent-method-140500520</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-granted-u-patent-method-140500520</guid>
      <pubDate>Wed, 12 Nov 2025 14:05:00 GMT</pubDate>
      <description>The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight lossLaromestrocel, a mesenchymal stem cell therapy, has delivered posi</description>
    </item>
    <item>
      <title>Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-announces-third-quarter-2025-210500273</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-announces-third-quarter-2025-210500273</guid>
      <pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
      <description>Than Powell Than Powell, CBO, Longeveron On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication and is fully enrolled.ELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyCompany to host con</description>
    </item>
    <item>
      <title>Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-report-third-quarter-2025-131500434</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-report-third-quarter-2025-131500434</guid>
      <pubDate>Tue, 28 Oct 2025 13:15:00 GMT</pubDate>
      <description>MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast D</description>
    </item>
    <item>
      <title>Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect</title>
      <link>https://6ix.com/company/longeveron-llc/news/longeveron-co-founder-chief-science-131500093</link>
      <guid isPermaLink="true">https://6ix.com/company/longeveron-llc/news/longeveron-co-founder-chief-science-131500093</guid>
      <pubDate>Mon, 27 Oct 2025 13:15:00 GMT</pubDate>
      <description>Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are anticipated in th</description>
    </item>
  </channel>
</rss>